Drug Development

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

A small biotech just unveiled data for an oral weight-loss pill that appears twice as effective as a key competitor in early tests, shaking up the market.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A new drug promises the brain-rewiring benefits of psychedelics without the trip. Can Clearmind Medicine's CMND-100 transform addiction treatment?

Sanofi deepens its partnership with Owkin, licensing its 'K Pro' platform to build autonomous AI agents. A look at the strategy behind this major bet.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

As NEXGEL prepares for a key investor conference, it faces a crucial test: convincing the market its advanced hydrogel tech can overcome recent financial hurdles.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

A new collaborative funding model is accelerating a revolutionary approach to ALS treatment, targeting the disease's core mechanism. Here's the why behind the buy.

Scispot's Series A targets the messy 'coordination gap' in labs. It's a bet that before we get self-driving labs, we must first fix the data pipes.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.